Tables S1 - S10 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Matti Annala(Tampere University), Alexander W. Wyatt(University of British Columbia), Daygen L. Finch(Interior Health), Kevin Beja(University of British Columbia), Christian K. Kollmansberger(BC Cancer Agency), Joanna Vergidis(BC Cancer Agency), Joonatan Sipola(Tampere University of Applied Sciences), Sinja Taavitsainen(Tampere University of Applied Sciences), Daniel Khalaf(BC Cancer Agency), Gillian Vandekerkhove(University of British Columbia), Conrad D. Oja(BC Cancer Agency), Martin Gleave(University of British Columbia), Matti Nykter(University of Liverpool), Simon Fu(BC Cancer Agency), Cameron Herberts(Natera (United States)), Bernhard J. Eigl(BC Cancer Agency), Evan W. Warner(Guardant (United States)), Amanda Wong(University of British Columbia), Muhammad Zulfiqar, Kim N.(Asian Institute of Technology)
Cited by 0
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k